Solymbic Европска Унија - Исландски - EMA (European Medicines Agency)

solymbic

amgen europe b.v. - adalimumab - arthritis, psoriatic; spondylitis, ankylosing; crohn disease; colitis, ulcerative; hidradenitis suppurativa; psoriasis; arthritis, rheumatoid - Ónæmisbælandi lyf - vinsamlegast skoðaðu kafla 4. 1 af samantekt á eiginleikum vöru í upplýsingaskjalinu.

Cyltezo Европска Унија - Исландски - EMA (European Medicines Agency)

cyltezo

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - Ónæmisbælandi lyf - vinsamlegast skoðaðu kafla 4. 1 af samantekt á eiginleikum vöru í upplýsingaskjalinu.

Lacosamide UCB Европска Унија - Исландски - EMA (European Medicines Agency)

lacosamide ucb

ucb pharma s.a. - lacosamíð - flogaveiki, partial - antiepileptics, - lacosamide ucb er ætlað eitt og sér og venjulega meðferð í meðferð á hluta-upphaf flog með eða án efri almenn ákvörðun er tekin í fullorðnir, unglingum og börn, frá 4 ára aldri með flogaveiki.

Hepcludex Европска Унија - Исландски - EMA (European Medicines Agency)

hepcludex

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - veirueyðandi lyf til almennrar notkunar - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Orladeyo Европска Унија - Исландски - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - ofsabjúgur, arfgengur - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Qinlock Европска Унија - Исландски - EMA (European Medicines Agency)

qinlock

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinal stromal tumors - Æxlishemjandi lyf - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.